Champions Oncology (CSBR) Stock Price, News & Analysis

Company Overview

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Key Stats

• Today's Range: $5.98 to $6.30
• 50-Day Range: $5.70 to $6.27
• 52-Week Range: $5.50 to $9.63
• Volume: 17,919 shs
• Average Volume: 7,070 shs
• Market Capitalization: $83.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Champions Oncology Stock Analysis - MarketRank™

Champions Oncology scored higher than 6% of companies evaluated by MarketBeat, and ranked 833rd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Champions Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Champions Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Champions Oncology is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Champions Oncology is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Champions Oncology has a P/B Ratio of 22.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.11% of the float of Champions Oncology has been sold short.

Short Interest Ratio / Days to Cover

Champions Oncology has a short interest ratio ("days to cover") of 10.82, which indicates bearish sentiment.

Change versus previous month

Short interest in Champions Oncology has recently increased by 0.11%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Champions Oncology does not currently pay a dividend.

Dividend Growth

Champions Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Champions Oncology has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Champions Oncology this week, compared to 5 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Champions Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CSBR Stock Analysis - Frequently Asked Questions

How have CSBR shares performed this year?

Champions Oncology's stock was trading at $6.9250 at the start of the year. Since then, CSBR stock has decreased by 13.6% and is now trading at $5.98.

How were Champions Oncology's earnings last quarter?

Champions Oncology, Inc. (NASDAQ:CSBR) announced its quarterly earnings data on Wednesday, July, 23rd. The biotechnology company reported ($0.13) earnings per share for the quarter. The biotechnology company had revenue of $12.35 million for the quarter. Champions Oncology had a negative trailing twelve-month return on equity of 57.31% and a negative net margin of 3.94%.
Read the conference call transcript.

Who are Champions Oncology's major shareholders?

Champions Oncology's top institutional investors include Bank of New York Mellon Corp (0.16%).
View institutional ownership trends.

How do I buy shares of Champions Oncology?

Shares of CSBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Champions Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 7/23/2025
• Today: 5/07/2026
• Next Earnings (Estimated): 7/16/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CSBR
• CIK: 771856
• Web: www.championsoncology.com
• Phone: (201) 808-8400
• Fax: 410-369-0390
• Employees: 143
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.70 million
• Net Margins: -3.94%
• Pretax Margin: -4.14%
• Return on Equity: -57.31%
• Return on Assets: -7.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.98
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $56.94 million
• Price / Sales: 1.46
• Cash Flow: $0.46 per share
• Price / Cash Flow: 13.02
• Book Value: $0.27 per share
• Price / Book: 22.15

Miscellaneous

• Outstanding Shares: 13,890,000
• Free Float: 7,363,000
• Market Cap: $83.06 million
• Optionable: Optionable
• Beta: 0.42